warfarin + fesoterodine

Warfarin + fesoterodine is a combination of two pharmaceutical agents, each with distinct mechanisms and indications. Warfarin is an oral anticoagulant that acts as a vitamin K antagonist, inhibiting the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and proteins C and S. It is primarily used for the prevention and treatment of thromboembolic disorders such as venous thromboembolism, pulmonary embolism, atrial fibrillation-related stroke risk reduction, and prosthetic heart valve thromboprophylaxis[8]. Fesoterodine is an antimuscarinic agent indicated for the treatment of overactive bladder with symptoms including urge urinary incontinence, urgency, frequency in adults and neurogenic detrusor overactivity in pediatric patients[4][6]. Fesoterodine acts as a competitive antagonist at muscarinic acetylcholine receptors (M1–M5), reducing involuntary bladder contractions[4][5]. Clinical studies have shown no significant pharmacokinetic or pharmacodynamic interaction between warfarin and fesoterodine when co-administered; both drugs maintain their efficacy and safety profiles when used together[1][2][3][5].

Other names

warfarinfesoterodine